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Abstract
Sexual violence is associated with increased risk of HIV acquisition/transmission in women.
Forced sex can result in physical trauma to the reproductive tract as well as severe psycho-
logical distress. However, immuno-biological mechanisms linking sexual violence and HIV
susceptibility are incompletely understood. Using the Women’s Interagency HIV Study
repository, a total of 77 women were selected to form 4 groups, stratified by HIV serostatus,
in the following categories: 1) no sexual abuse history and low depressive symptom score
(below clinically significant cut-off, scores <16) (Control); 2) no sexual abuse history but high
depressive symptom score,16 (Depression); 3) chronic sexual abuse exposure and low
depressive symptom score (Abuse); 4) chronic sexual abuse exposure and high depressive
symptom score (Abuse+Depression). Inflammation-associated cytokines/chemokines/pro-
teases (TNF-α, IL-6, IL-1α, IL-1β, TGF-βMIP-3α, IP-10, MCP-1, Cathepsin B), anti-inflam-
matory/anti-HIV mediators (Secretory leukocyte protease inhibitor (SLPI), Elafin, beta
defensin 2 (HBD2), alpha defensins (HNP 1–3), Thrombospondin (TSP-1), Serpin A1, A5,
Cystatin A, B), and wound-healing mediators (Gro-α, VEGF, PDGF, EGF, FGF, IGF), were
measured in cervical-vaginal lavage (CVL) using ELISA. Linear regression was used to
model association of biomarkers with depression and abuse as predictor variables; the inter-
action between depression and abuse was also tested. Anti-HIV activity in CVL was tested
using TZM-bl indicator cell line. In HIV-uninfected women, median levels of IL-6 (p = 0.04),
IL-1α (p<0.01), TGF-β (p = 0.01), IP-10 (p = <0.01), PDGF (p<0.01) and FGF (p<0.01), dif-
fered significantly between groups. Specifically, an association was found between chronic
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sexual abuse and increased IL-1α (p<0.01), MIP-3α (p = 0.04), IP-10 (p<0.01), Serpin B1
(p = 0.01), FGF (p = 0.04) and decreased TGF-β (p<0.01), MCP-1 (p = 0.02), PDGF
(p<0.01). Further, there was evidence of significant interactions between chronic sexual
abuse and current depression for IL-1α, IP-10, Serpin A1, Cystatin B, and FGF. In HIV-
infected women, median levels of TNF-α (p<0.01), IL-6 (p = 0.05), MIP-3α (p<0.01), and
MCP-1 (p = 0.01), differed significantly between groups. Specifically, an association was
found between chronic sexual abuse and increased MCP-1 (p = 0.03), Gro-α (p = 0.01) and
decreased TNF-α (p<0.01), IL-1α (p = 0.02), MIP-3α (p<0.01) and Cathepsin B (p = 0.03).
Current depressive symptoms were associated with significantly decreased MIP-3α
(p<0.01). There was evidence of significant interactions between chronic sexual abuse and
current depression for MCP-1 and FGF. No significant differences were observed in anti-
HIV activity among all eight groups. Heat-map analyses revealed distinct immune network
patterns, particularly in the Abuse groups for both HIV-infected and uninfected women. Our
data indicates a complex relationship between chronic sexual abuse exposure, depressive
symptoms, and FRT immune mediators that are also affected by HIV status. Association of
chronic sexual abuse with increase in inflammation-associated cytokine/chemokine expres-
sion, along with impaired wound-healing associated growth-factors can create a microenvi-
ronment that can facilitate HIV infection. Evaluation of longitudinal changes in exposures
and biomarkers are needed to untangle the immuno-biological mechanisms that may put
women who endure life-long sexual abuse at increased risk for HIV.
Introduction
Violence and HIV/AIDS form a tragic feedback loop that disproportionately affects women
worldwide [1]. In the United States alone, partner violence and sexual assault are the first and
sixth leading causes of injury in women, respectively [2],[3]. Globally, it is estimated that about
1 in 3 women experience physical violence in their lifetimes, most of which is committed by an
intimate partner [4]. Women are also more likely to be affected by the HIV/AIDS epidemic.
As of 2015, 51% of all HIV infections were in women, with the greatest burden (60%) among
young adults [5]. Violence against women has been significantly associated with increased risk
of HIV acquisition/transmission [1],[6].
Heterosexual sex is the most common route of HIV infection in women [7]. Several attri-
butes of the female reproductive tract (FRT) can modulate susceptibility to HIV infection,
including the presence of the sex hormones estrogen and progesterone. The sex hormones
modulate sexually transmitted infection (STI) susceptibility throughout the menstrual cycle by
affecting the mucosal environment within the FRT [8], [9]. Recent studies have identified the
secretory phase as being a window of increased HIV susceptibility [9]. Susceptibility to infec-
tion is also increased by the presence of cervico-vaginal lymphocytes (which can be activated
in response to injury) and dysregulation of epithelial tight junctions within the FRT (which
results in increased permeability and increased access for pathogens) [8],[9].
The impact of sexual violence on the FRT is of particular interest to HIV acquisition/trans-
mission because most sexual assaults involve vaginal penetration [3]. There are many physical
changes that occur within the FRT after sexual assault that can be associated with increased
risk of HIV transmission, including vaginal lacerations, abrasions, and inflammation [3],[10].
Alterations to T-cell function and slower wound healing have also been reported in survivors
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of violence, both of which are factors that increase susceptibility to HIV infection [6]. Wounds
resulting in damaged mucosal surfaces are estimated to occur in 22–90% of all sexual assaults
[3].
Wound healing is a dynamic process that is tightly regulated by the timed sequential release
of cytokines, chemokines, proteases/anti-proteases and growth factors by platelets, macro-
phages, neutrophils, and fibroblasts [11],[12]. The process begins when inflammation occurs
as a result of mucosal trauma and injury (as from sexual assault). The repair process begins
immediately with sequential release of specific immune factors that act to control inflamma-
tion and recruit the cells necessary for repair. This is followed by new tissue formation and
remodeling, which can take weeks to months [11],[12]. Improper/untimely expression of any
of these mediators can result in delayed wound healing and increased susceptibility to patho-
gens such as HIV [12][13]. Expression of soluble immune mediators involved in the wound
healing process can be affected by factors such as the presence of infections, history of chronic
injury, age and stress, as well as behavioral variables such as smoking and alcohol consumption
[14]. Mucosal wound healing is also gender-specific with significantly delayed healing reported
in women compared to men [15] [16]. Further, many of the mediators are regulated by sex
hormones and hence vary throughout the menstrual cycle [17]. The anti-inflammatory/anti-
proteases such as SLPI [18] and Elafin [19], which are critical for timely control of the initial
inflammatory response, also have direct HIV inhibitory functions [20]. Whereas it is known
that HIV-infected individuals experience chronic inflammatory conditions even while on anti-
retroviral therapy [21], studies are limited on how wound healing pathways are affected in
HIV-infected women, particularly those exposed to sexual violence.
In addition to the physical effects of violence, those exposed to it are more likely to engage
in high-risk sexual behaviors. For example, intimate partner violence (IPV) victims are more
likely to have transactional and unprotected sex, and are less likely to be tested for HIV [1],[6].
Women in abusive relationships are at increased risk of contracting an STI as well as suffer
from depression, than women that are in relationships that are abuse free. [6],[22]. HIV status
is also associated with IPV, with HIV-infected women in the United States experiencing dou-
ble the rate of IPV as HIV-uninfected women [6]. Further, depression is a common occurrence
in women who have experienced violence [23], and depression is known to negatively impact
the immune system [24]. A recent meta-analysis that included 37 studies [23] found 2-3-fold
increased risk of major depressive disorder in women exposed to intimate partner violence
(IPV), particularly in those experiencing life-time chronic exposure. In terms of immune dys-
regulation, depression has been associated with both immune activation (increase in pro-
inflammatory mediators such as IL-6, TNF-α, CRP, IL1) and immune suppression (loss of T
cell and NK cell function) (reviewed [25]). Pro-inflammatory cytokines endogenously pro-
duced in the brain can directly impact depressive symptoms by affecting neuronal growth and
plasticity [26] and a handful of studies have reported anti-cytokine therapy to effectively
reduce depressive symptoms [27]. In addition, certain polymorphisms in TNF-α, which can
directly activate serotonin pathways in the brain, have been linked to major depressive illnesses
[28]. Depressive symptoms have also been associated with dysregulation of HPA axis and cor-
tisol mediated stress response (reviewed [29]). Finally, there is some evidence of association
between depressive symptoms and significantly slower rates of mucosal wound healing [30].
Although causality of inflammation/immune dysregulation and depression are difficult to
prove, a study by Das [31] found inflammation to be a predictor of psychosocial distress.
Overall, there is limited data available to help us with our understanding of the specific
immuno-biological mechanisms associated with sexual abuse exposure, depressive symptoms,
and HIV status, individually and in combination. In this study, we sought to identify differ-
ences in FRT immune mediators by HIV status based on sexual abuse histories and current
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depressive symptoms. We hypothesized that women with the greatest burden of chronic sexual
abuse and current depressive symptoms would have a genital immune dysregulation pattern
of high inflammation/immune activation and impaired wound healing pathways which can
negatively impact risk of HIV acquisition/transmission.
Materials and methods
Ethical statement
The Women’s Interagency HIV Study (WIHS) protocol and this study were conducted
according to the principles expressed in the Declaration of Helsinki. After approval by each
participating institution’s review board, study staff obtained written informed consent for the
collection and use of data and specimens from each research participant. All participants con-
sented to future use of their data and their specimens in the repository. This study was deter-
mined to not meet the definition of human subjects research by The George Washington
University IRB, as all our analyses involved de-identified samples without access to any code-
link.
Study participants and demographics
WIHS is an ongoing prospective observational cohort study of HIV-infected and sociodemo-
graphically similar uninfected women in the United States. Study methods, baseline cohort
characteristics, and long-term retention have been previously described [32–34]. Briefly, semi-
annual visits included an in-depth interview for collection of demographic, behavioral, and
clinical factors, a physical and gynecologic exam with specimen collection for the repository.
For this cross-sectional study, participants were selected from either the 1994–95 or 2001–02
WIHS enrollment periods based on the following criteria: complete baseline and longitudinal
childhood and adult abuse data, as well as, not pregnant at visit, breast feeding, or lacking a
cervix as a result of hysterectomy. Individuals selected based on these criteria were then cate-
gorized based on their self-reported sexual abuse histories.
In both HIV-infected and uninfected women, we identified sexual abuse groups represent-
ing life-long history of multiple types of sexual abuse exposure (childhood and adult sexual
abuse including any reported transactional sex), which we defined as “chronic sexual abuse”.
Comparison groups (Controls) had never been exposed to sexual abuse. From among visits
with cervicovaginal lavage (CVL) aliquots available in the repository, we selected a visit associ-
ated with concurrent sexual abuse exposure. We then further stratified visits based on the level
of concurrent self-reported depressive symptoms using the Center for Epidemiologic Studies-
Depression (CES-D) [35]) Scale. This is a measure that asks questions about symptoms associ-
ated with depression. Scores range from 0 to 60, with high scores indicating greater depressive
symptoms; a score of>16 is used as a cut-off for clinical depression ([36], [37]).
Visits from a total of 77 women were selected to form 4 groups stratified by HIV serostatus
in the following categories: 1) no sexual abuse history and low depressive symptom score
(below clinically significant cut-off, scores <16) (Control); 2) no sexual abuse history but high
depressive symptom score,16 (Depression); 3) chronic sexual abuse exposure and low
depressive symptom score (Abuse); 4) chronic sexual abuse exposure and high depressive
symptom score (Abuse+Depression). Plasma viral load and CD4 counts in HIV-infected
women, were obtained from WIHS database. CVL viral loads were also quantified; however,
almost 100% of the samples were undetectable at a detection level of 40 copies/mL. All HIV-
infected women were on highly active antiretroviral therapy (HAART).
Sexual violence and genital immune biomarkers in women
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Measurement of cytokines, chemokines, and antimicrobials in cervico-
vaginal lavage
CVL samples were obtained from WIHS repository and stored at –80˚ C until assayed for cyto-
kines: TNF-α, IL-6, IL-1α, IL-1β, TGF-β; chemokines: MIP-3α, IL-8, MCP-1, IP-10; antimi-
crobial/antiproteases: secretory leukocyte protease inhibitor (SLPI), Elafin, Human beta
defensin 2 (HBD2), Human alpha defensins 1–3 (HNP 1–3), Thrombospondin (TSP-1), Ser-
pin A1, Serpin A5, Cystatin A, Cystatin B; growth factors/proteases: Gro-α, vascular endothe-
lial growth factor (VEGF), platelet derived growth factor (PDGF), epidermal growth factor
(EGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF), and Cathepsin B with
ELISA Quantikine or Duoset kits. All except HBD-2, Serpin A1, B1 and Cystatin A, were pur-
chased from R&D Systems (Minneapolis, MN), and assays were performed according to the
manufacturer’s protocols. HBD2 was assayed using an ELISA test kit from PeproTech (Rocky
Hill, NJ). Serpin A1, B1 and Cystatin A ELISA kits were purchased from Lifespan Biosciences
(Seattle, Washington). All immune mediators were quantified based on standard curves
obtained using a Microplate Reader (Biotek, Winooski, VT). Biomarker concentrations below
the lower limit of detection were reported as the mid-point between the lowest concentrations
measured and zero.
Total protein analysis
Total protein concentration in CVL samples was determined using the Pierce BCA protein
assay kit (Thermo-Fisher Scientific), following manufacturer’s instructions.
HIV viral stocks
Laboratory-adapted HIV-1 strain BaL was kindly provided by Dr. P. Gupta (University of
Pittsburgh, PA). We also used HIV-1 transmitted/founder (T/F) strain RHPA.c, a Clade B
infectious molecular clone (IMC)[38] matching the inferred T/F virus nucleotide sequence
from subject RHPA4259 and isolated from a heterosexually-infected female subject (kindly
provided by Dr. Christina Ochsenbauer, University of Alabama at Birmingham, AL). Virus
stocks were propagated in PHA-stimulated human PBMC and stored frozen at −80˚ C. Virus
titers were determined on TZM-bl cells.
HIV inhibition analysis
Anti-HIV activity in CVL was determined using TZM-bl indicator cell-line (AIDS reagent
Repository, NIH), essentially as previously described [39]. Cells were seeded at 2×104 cells per
well in a 96-well plate, and allowed to adhere overnight at 37˚ C. CVL samples were diluted 1:4
in TZM-bl media (phenol red-free DMEM (Invitrogen Life Technologies, Carlsbad, CA) sup-
plemented with 10% defined FBS (HyClone, Logan, UT), 2 mM L-glutamine (Invitrogen Life
Technologies), and 50 μg/mL Primocin (Invivogen, San Diego, CA) and incubated with a labo-
ratory-adapted HIV-1 strain BaL, as well as a heterosexually transmitted (T/F) strain RHPA.c
(at 250 tissue culture infectious dose (TCID50). The dose was selected to minimize virus-
induced cytopathic effects, while maintaining an ability to measure>1 log reduction in virus
infectivity (standardized by [40]). Samples were incubated with virus for 1 hour at 37˚ C and
added to TZM-bl cells. Luciferase activity was measured after 48h upon application of sub-
strate beta-Glo (Promega, Madison, WI). Uninfected cells and cells treated with CVL alone
were used to determine background luminescence expressed as relative light units (RLU). All
conditions were tested in triplicates and repeated twice. To calculate percent inhibition, RLU
values of “virus only” wells were averaged and set to 100%. Viability of cells upon treatment
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with CVL was quantified using the CellTiter 961 AQueous One Solution Cell Proliferation
Assay (Promega) according to manufacturer’s instructions. Briefly, reagent was added directly
to cell cultures and incubated for 30 min at 37˚ C followed by reading the plate in a plate reader
at OD 490 nm.
Statistical analyses
Possible covariates that can affect immune biomarkers in the context of our study of interest
were compared across the four groups, separately by HIV status; chi-square or Fishers exact
test was used for categorical variables, and the Kruskal-Wallis test for continuous variables. All
biomarker level values were log-transformed as they were not normally distributed. The
median log-transformed values of each biomarker were compared by group, using the Krus-
kal-Wallis test. For biomarkers with significant differences in medians, graphs were created
using R Studio version 1.0.136 with Mann-Whitney U tests comparing each group to the
control.
Heat-maps for each group were constructed to assess the direction and strength of associa-
tions between individual biomarkers and other functional and clinical variables such as HIV
inhibition, CD4, and plasma viral load data by performing Spearman’s rank-order correlation
tests using R Studio version 1.0.136.
We ran linear regression models, separately for HIV- uninfected and HIV-infected women,
for each immune mediator. For HIV-uninfected women, we ran unadjusted analyses with
both abuse and depression as predictors. Due to the small sample size, we did not adjust mod-
els for hormonal contraception or Bacterial Vaginosis (BV), covariates which can be associated
with biological changes in the FRT [41,42].
Models for HIV-infected women were adjusted for CD4+ T cell count and plasma HIV
viral load. Final models included an interaction term between abuse and depression.
Models including all women were used to assess effect modification by HIV status. For
each biomarker, the predictors included abuse, depression, HIV status and two interaction
terms: HIV status and abuse, and HIV status and depression. These terms tested whether the
difference between women who reported chronic sexual abuse versus no abuse (or reported
depressive symptoms vs no symptoms) differed by HIV status. Given the large numbers of
models and outcomes tested, we highlight results that remained significant after using a Bon-
ferroni correction. These analyses were conducted in SAS 9.4.
Results
Characteristics of study samples
Among HIV-uninfected women (Table 1A), women in the Control group were younger
(p<0.01) and in the higher income category (p<0.001). Women who were not Controls were
more likely to be current smokers (p<0.01), report substance use (p<0.01) and consume more
alcoholic drinks per week (Abuse+Depression group) (p<0.01), compared to the other groups.
Women in the Abuse+Depression group were more likely to have reported transactional sex
since last visit (p = 0.03). Women also differed significantly in terms of any abuse history
(P<0.01), any abuse since last visit (p<0.01), childhood sexual and physical abuse (p<0.01)
and adult physical abuse history (P<0.01), in addition to the selection criteria variables of cur-
rent depression and sexual abuse exposures (p<0.01).
Among HIV-infected participants (Table 1B), Control women were more likely to be edu-
cated (p = 0.03) and employed (p<0.01). Women in the Abuse+ Depression group had more
male sexual partners in the past 6 months (p<0.01) and higher reported substance use
(p<0.01). Women also differed significantly in terms of any abuse history (P<0.01), any abuse
Sexual violence and genital immune biomarkers in women
PLOS ONE | https://doi.org/10.1371/journal.pone.0198412 June 12, 2018 6 / 23
Table 1. Participant characteristics among (A) HIV-uninfected and (B) HIV-infected women. Any Abuse history includes emotional, physical, sexual abuse. SLV:
Since last visit, in the past 6 months. Some categories have missing values and therefore, might not add up to the sample size for that group.
1A. HIV-uninfected
Variable No Depression, No Abuse, %
(N)
Depression Only, %
(N)
Abuse Only, %
(N)
Depression & Abuse, %
(N)
p-
value
N 10 11 10 8
Demographics
Age, Median (IQR) 35.2 (30.6–39.5) 47.9 (46.8–48.8) 41.0 (39.4–49.5) 41.8 (34.5–44.1) <0.01
Race 0.15
White 20.0 (2) 36.4 (4) 50.0 (5) 12.5 (1) .
African-American 80.0 (8) 36.4 (3) 40.0 (4) 75.0 (6) .
Other 0.0 (0) 27.3 (3) 10.0 (1) 12.5 (1) .
Education 0.39
<HS 10.0 (1) 54.5 (5) 11.1 (1) 37.5 (3) .
HS 20.0 (2) 18.2 (2) 22.2 (2) 25.0 (2) .
>HS 70.0 (7) 27.3 (3) 66.7 (6) 37.5 (3) .
Income <0.01
<$12,000 0.0 (0) 60.0 (6) 44.4 (4) 50.0 (3) .
<$24,000 0.0 (0) 20.0 (2) 11.1 (1) 50.0 (3) .
>$24,000 100.0 (10) 20.0 (2) 44.4 (4) 0.0 (0) .
Employed 80.0 (8) 27.3 (2) 33.3 (3) 37.5 (3) 0.07
Reproductive status and sexual behavior
# Male Sex Partners (last 6 months), Median
(IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–5.0) 0.22
Vaginal Sex with Male last 48 hrs 20.0 (2) 9.1 (1) 11.1 (1) 25.0 (2) 0.82
Condom Use During Vaginal Sex 0.54
Always 33.3 (3) 44.4 (4) 12.5 (1) 0.0 (8) .
Sometimes 33.3 (3) 11.1 (1) 37.5 (3) 28.6 (2) .
Never 33.3 (3) 44.4 (4) 50.0 (4) 71.4 (5) .
Anal Sex SLV 0.0 (0) 0.0 (0) 12.5 (1) 0.0 (0) 0.7
Transactional Sex SLV 0.0 (0) 0.0 (0) 0.0 (0) 25.0 (2) 0.03
BV by Amsel at visit 12.5 (1) 12.5 (1) 10.0 (1) 0.0 (0) 1
Been Through Menopause 0.0 (0) 27.3 (3) 22.2 (2) 12.5 (1) 0.31
Hormonal Contraception last 6 months 10.0 (1) 18.2 (2) 10.0 (1) 0.0 (0) 0.89
Other risk behavior and abuse/depression
status
Current Smoker 10.0 (1) 81.8 (9) 22.2 (2) 50.0 (4) <0.01
Ever use crack, cocaine, or heroin 10.0 (1) 90.9 (10) 66.7 (6) 75.0 (6) <0.01
Drinks per week, Median (IQR) 0.7 (0.1–1.5) 0.0 (0.0–5.5) 0.0 (0.0–0.1) 12.3 (4.3–26) <0.01
CESD, Median (IQR) 0.0 (0.0–0.0) 42.0 (32.0–44.0) 6.5 (5.0–10.0) 26.5 (23.5–33.0) <0.01
Any Abuse history 40.0 (4) 81.8 (8) 100 (9) 100 (8) <0.01
Any Abuse SLV 0.0 (0) 10.0 (1) 22.2 (2) 62.5 (5) <0.01
Childhood Sexual Abuse 0.0 (0) 0.0 (0) 100 (10) 100 (8) <0.01
Childhood Physical Abuse 0.0 (0) 18.2 (2) 66.7 (6) 37.5 (3) <0.01
IPV history 10.0 (1) 36.4 (4) 66.7 (6) 50.0 (4) 0.07
IPV SLV 0.0 (0) 9.1 (1) 11.1 (1) 37.5 (3) 0.12
Sexual Abuse history 0.0 (0) 0.0 (0) 100 (10) 100 (8) <0.01
Sexual Abuse SLV 0.0 (0) 0.0 (0) 0.0 (0) 25.0 (2) .
Physical Abuse history 30.0 (3) 72.7 (7) 100 (9) 100 (8) <0.01
(Continued)
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Table 1. (Continued)
Physical Abuse SLV 0.0 (0) 9.1 (1) 10.0 (1) 37.5 (3) 0.12
1B. HIV-infected
Variable No Depression, No Abuse, %
(N)
Depression Only, %
(N)
Abuse Only, %
(N)
Depression & Abuse, %
(N)
p-
value
N 10 10 8 10
Demographics
Age, Median (IQR) 46.4 (43.8–54.1) 44.3 (39.3–46.0) 44.6 (40.9–48.2) 43.2 (36.4–52.0) 0.41
Race 0.84
White 10.0 (1) 20.0 (2) 12.5 (1) 10.0 (1) .
African-American 80.0 (8) 60.0 (6) 75.0 (6) 90.0 (9) .
Other 10.0 (1) 20.0 (2) 12.5 (1) 0.0 (0) .
Education 0.03
<HS 0.0 (0) 70.0 (7) 37.5 (3) 50.0 (5) .
HS 30.0 (3) 10.0 (1) 12.5 (1) 10.0 (1) .
>HS 70.0 (7) 20.0 (2) 50.0 (4) 40.0 (4) .
Income 0.34
<$12,000 33.3 (3) 50.0 (5) 57.1 (4) 80.0 (8) .
<$24,000 22.2 (2) 40.0 (4) 28.6 (2) 10.0 (1) .
>$24,000 44.4 (4) 10.0 (1) 14.3 (1) 10.0 (1) .
Employed 70.0 (7) 30.0 (3) 25.0 (2) 0.0 (0) <0.01
Reproductive status and sexual behavior
# Male Sex Partners (last 6 months), Median
(IQR)
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.50 (1.0–2.0) <0.01
Vaginal Sex with Male last 48 hrs 20.0 (2) 0.0 (0) 12.5 (1) 0.0 (0) .
Condom Use During Vaginal Sex 0.24
Always 70.0 (7) 57.1 (4) 50.0 (4) 22.2 (2) .
Sometimes 0.0 (0) 25.0 (2) 33.3 (3) .
Never 30.0 (3) 42.9 (3) 25.0 (2) 44.4 (4) .
Anal Sex SLV 0.0 (0) 0.0 (0) 0.0 (0) 14.3 (1) 0.43
Transactional Sex SLV 0.0 (0) 0.0 (0) 0.0 (0) 10.0 (1) 1
BV by Amsel at visit 12.5 (1) 30.0 (3) 12.5 (1) 66.7 (6) 0.06
Been Through Menopause 20.0 (2) 0.0 (0) 12.5 (1) 20.0 (2) 0.57
Hormonal Contraception last 6 months 10.0 (1) 10.0 (1) 12.5 (1) 0.0 (0) 0.88
Other risk behavior and abuse/depression
status
Current Smoker 20.0 (2) 50.0 (5) 25.0 (2) 70.0 (7) 0.11
Ever use crack, cocaine, or heroin 10.0 (1) 30.0 (3) 62.5 (5) 90.0 (9) <0.01
Drinks per week, Median (IQR) 0.0 (0.0–0.1) 0.0 (0.0–1.3) 0.4 (0.0–1.4) 1.5 (0.2–4.8) 0.07
CESD, Median (IQR) 0.0 (0.0–0.0) 36.5 (34.0–39.0) 4.5 (2.0–6.0) 38.5 (33.0–42.0) <0.01
Any Abuse History 50.0 (5) 40.0 (4) 100 (8) 100 (10) <0.01
Any Abuse SLV 0.0 (0) 0.0 (0) 12.5 (1) 40.0 (4) 0.01
Childhood Sexual Abuse 0.0 (0) 0.0 (0) 100 (8) 100 (10) <0.01
Childhood Physical Abuse 20.0 (2) 10.0 (1) 37.5 (3) 66.7 (6) 0.06
IPV History 20.0 (2) 10.0 (1) 25.0 (2) 90.0 (9) <0.01
IPV SLV 0.0 (0) 0.0 (0) 12.5 (1) 40.0 (4) 0.01
Sexual Abuse History 0.0 (0) 0.0 (0) 100 (8) 100 (10) <0.01
Sexual Abuse SLV 0.0 (0) 0.0 (0) 0.0 (0) 30.0 (3) <0.01
Physical Abuse History 50.0 (5) 40.0 (4) 87.5 (7) 100 (10) <0.01
Physical Abuse SLV 0.0 (0) 0.0 (0) 0.0 (0) 30.0 (3) 0.04
(Continued)
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since last visit (p = 0.01), childhood sexual abuse, IPV history and IPV since last visit (p<0.01),
physical abuse history and since last visit (p<0.01), in addition to the selection criteria vari-
ables of current depression and sexual abuse exposures (p<0.01). There were no differences in
CD4 count, plasma viral load, and HAART usage between the groups.
For both HIV-uninfected and infected women, there were no differences by race, presence
of bacterial vaginosis, BV status, or menopause (Table 1A and 1B).
Changes in cervico-vaginal immune mediators by abuse or depression
status in HIV-uninfected women
Median concentrations of the chemokine IP-10 were highest in the Abuse+Depression group
(2.78 log pg/mL), followed by the Abuse (2.00 log pg/mL), and Control (1.39 log pg/mL)
groups. The Depression group was mostly undetectable (1.24 log pg/mL) and significantly
lower (p<0.01) (Fig 1A, Table 2A). A similar trend was observed for pro-inflammatory cyto-
kine IL-1α levels with Abuse+Depression being the highest (2.79 log pg/mL), followed by the
Abuse (2.13 log pg/mL) and the Control (1.93 log pg/mL) groups. The Depression group was
mostly not detectable (0.42 log pg/mL) and significantly lower (p<0.01). (Fig 1B, Table 2A).
Median values for another pro-inflammatory cytokine, IL-6, were also highest in the Abuse
group and lowest in the Depression group (p = 0.04) (Fig 1C). In contrast, for the growth fac-
tor and wound healing mediator PDGF, highest median values were seen in the Control group
(3.09 log pg/mL), followed by the Depression (2.74 log pg/mL) group and significantly lower
levels in Abuse (1.60 log pg/mL) and Abuse+Depression (0.78 log pg/mL) groups (p<0.01)
(Fig 1D, Table 2A).
Median concentrations of the anti-inflammatory cytokine TGF-β were highest in the
Depression group (1.78 log pg/mL), followed by significantly lower and mostly undetectable
values for Control (0.26 log pg/mL), Abuse (0.26 log pg/mL) and Abuse+Depression groups
(0.26 log pg/mL) (p<0.01) (Table 2A).
Using linear regression analysis, current depressive symptoms (after controlling for chronic
sexual abuse), was not significantly associated with any difference in levels of biomarkers
(Table 3A). However, chronic sexual abuse (after controlling for depressive symptoms) was
associated with a 0.68 pg/mL log increase of MIP-3α (p = 0.04), 0.95 pg/mL log increase of IL-
1α (p = 0.01), 0.67 pg/mL log increase of IP-10 (p<0.01), and a 0.53 pg/mL log increase of Ser-
pin B1 (p = 0.01) (Table 3A). Chronic sexual abuse was also associated with a 0.76 pg/mL log
decrease of MCP-1 (p = 0.02), 1.49 pg/mL log decrease of PDGF (p<0.01), and a 0.71 pg/mL
log decrease in TGF-β (p<0.01) (Table 3A). Since CVL samples can have variable protein con-
tent [43,44], we measured total protein in each CVL sample and adjusted each mediator to the
protein content in that. All values remained significant before and after protein adjustment
except IL-6 and FGF (Tables 2A and 3A). Interaction between chronic sexual abuse and cur-
rent depressive symptoms was significant for IL-1α, IP-10, Cystatin B, Serpin A1 and FGF
(before protein adjustment), which suggests that the relationship between chronic sexual
abuse and these markers differs by depressive symptoms, or vice versa (Table 3A). FGF did not
remain significant following protein adjustment (Table 3A).
Table 1. (Continued)
Clinical parameters
CD4 Count 475 (395–660) 739 (523–1086) 693 (557–782) 539 (445–702) .
Log Viral Load 1.5 (1.3–2.6) 1.7 (1.7–1.8) 1.3 (1.3–2.7) 2.4 (1.3–4.0) 0.58
On HAART 100 (10) 100 (10) 100 (8) 100 (10) .
https://doi.org/10.1371/journal.pone.0198412.t001
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Changes in cervico-vaginal immune mediators by abuse or depression
status in HIV-infected women
Median concentrations of the chemokine MIP-3α were highest in the Control group (1.36 log
pg/mL), followed by Depression (1.05 log pg/mL) and mostly undetectable levels in Abuse
(-0.67 log pg/mL) and Abuse+Depression groups (-0.67 log pg/mL) (p<0.01) (Fig 2A,
Table 2B). For another chemokine MCP-1, median concentrations were highest in the Abuse
group (2.58 log pg/mL), followed by Depression (2.36 log pg/mL) and Abuse+Depression
(2.21 log pg/mL) with mostly undetectable values for Controls (p = 0.01) (Fig 2B, Table 2B).
Concentrations of the pro-inflammatory cytokine IL-6 were highest in the Abuse+Depression
group (1.10 log pg/mL), followed by Abuse (1.08 log pg/mL), Depression (0.97 log pg/mL) and
Control (0.58 log pg/mL) (p = 0.05) (Fig 2C, Table 2B). Median concentrations of another
pro-inflammatory cytokine TNF-α were highest in the Depression (1.47 log pg/mL) group,
Fig 1. Differences in cervico-vaginal immune mediators by abuse status in HIV-uninfected women. CVL from Control women with no history of sexual abuse and
depression (n = 10), women with current depression (n = 11), women with history of chronic sexual abuse (n = 10), and women with history of chronic sexual abuse and
current depression (n = 8), were tested for levels of (A) IP-10, (B) IL-1α, (C) IL-6 and (D) PDGF by standard ELISA assays. Data is presented as log pg/mL of protein.
Bars depict median. P value is indicated as follows: , p<0.0001; , P<0.001; ,. P<0.05.
https://doi.org/10.1371/journal.pone.0198412.g001
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Table 2. Levels of cervicovaginal immune mediators in HIV-uninfected (A) and HIV-infected (B) women with history of abuse, depression, or both abuse and
depression. Data is presented in log pg/mL. Significant p-values denote differences in medians and are shown in bold. SLPI: secretory leukocyte protease inhibitor.
HBD2: human beta defensin-2. HNP 1–3: human alpha defensin 1–3. TSP-1: Thrombospondin-1.
2A. HIV Uninfected
Variable (Log10 pg/
mL)
Control Median
(IQR)
Depression Median
(IQR)
Abuse Median
(IQR)
Abuse+Depression Median
(IQR)
p
value
p value After Protein
Adjustment
n 10 11 10 8
TNF-α -1.6 (-1.6–1.76) 0.89 (-1.6–2.24) 1.30 (-1.6–1.43) 1.25 (1.07–1.40) 0.53 0.23
IL-6 0.66 (0.18–0.81) -0.71 (-0.71–0.71) 0.74 (0.44–0.86) 0.59 (0.37–0.74) 0.04 0.36
IL-1α 1.93 (0.42–2.29) 0.42 (0.42–1.87) 2.13 (0.42–2.67) 2.79 (2.72–2.88) <0.01 0.05
IL-1β 1.58 (0.31–1.99) 0.31 (0.31–1.59) 1.15 (0.31–1.62) 1.76 (0.31–2.04) 0.19 0.35
TGF-β 0.26 (0.26–1.62) 1.56 (0.26–2.35) 0.26 (0.26–0.26) 0.26 (0.26–0.26) 0.01 0.01
MIP-3α 1.03 (-0.37–1.91) 0.90 (-0.67–1.36) 1.82 (1.05–1.88) 1.65 (1.10–1.89) 0.24 0.23
IL-8 2.62 (2.32–2.96) 2.51 (1.97–2.74) 2.63 (2.48–3.08) 2.82 (1.81–3.14) 0.82 0.87
MCP-1 1.27 (0.02–2.05) 1.77 (0.02–2.33) 0.02 (0.02–1.74) 0.02 (0.02–0.02) 0.13 0.06
IP-10 1.39 (1.24–2.32) 1.24 (1.24–2.32) 2.00 (1.24–2.43) 2.78 (2.56–3.12) <0.01 0.01
SLPI 4.91 (4.54–5.15) 4.58 (4.00–5.04) 4.99 (4.31–5.34) 5.14 (4.35–5.51) 0.45 0.67
Elafin 5.34 (5.16–5.55) 5.25 (5.05–5.61) 5.15 (5.03–5.33) 5.36 (5.25–5.49) 0.32 0.86
HBD-2 3.73 (3.28–4.10) 3.64 (3.10–4.39) 3.38 (2.81–4.22) 3.73 (3.44–4.14) 0.71 0.78
HNP1-3 4.46 (3.70–5.15) 3.70 (3.70–4.95) 4.53 (4.38–5.46) 4.77 (3.96–5.09) 0.67 0.79
TSP-1 3.16 (2.83–3.32) 2.85 (2.62–3.00) 3.09 (2.87–3.32) 3.18 (3.03–3.53) 0.08 0.54
Serpin A1 5.50 (4.89–5.86) 4.68 (4.46–5.31) 5.20 (4.43–5.78) 5.54 (5.05–5.76) 0.2 0.08
Serpin A5 1.47 (1.47–1.47) 1.47 (1.47–2.61) 1.47 (1.47–2.40) 1.47 (1.47–2.23) 0.88 0.75
Serpin B1 2.87 (2.87–3.81) 2.87 (2.87–4.09) 4.01 (2.87–4.17) 4.02 (3.91–4.21) 0.14 0.15
Cystatin A 4.74 (4.58–5.47) 4.37 (3.53–5.75) 4.74 (4.37–5.06) 4.65 (3.23–5.58) 0.98 0.99
Cystatin B 4.40 (4.05–4.96) 2.86 (2.86–5.05) 2.86 (2.86–2.86) 4.40 (2.86–4.84) 0.09 0.08
GRO-α 1.97 (0.89–2.79) 1.19 (0.89–3.22) 2.60 (0.89–2.87) 2.69 (2.36–3.10) 0.5 0.35
VEGF 0.48 (0.48–0.48) 0.48 (0.48–0.48) 0.48 (0.48–2.02) 1.08 (0.48–2.08) 0.28 0.5
PDGF 3.09 (2.61–3.35) 2.74 (2.69–2.92) 1.60 (0.63–2.25) 0.78 (0.63–1.81) <0.01 <0.01
EGF 1.30 (0.34–1.55) 0.56 (-.24–0.88) -0.24 (-0.24–1.47) -0.24 (-0.24–0.49) 0.12 0.19
FGF 1.28 (1.28–1.28) 1.28 (1.28–1.28) 1.28 (1.28–1.28) 1.28 (1.28–1.92) <0.01 0.61
IGF 1.29 (1.29–2.36) 1.29 (1.29–1.29) 1.29 (1.29–2.05) 1.94 (1.29–2.87) 0.36 0.63
Cathepsin B 4.21 (4.03–4.52) 4.19 (3.77–4.41) 4.13 (3.80–4.30) 4.05 (3.84–4.24) 0.67 0.38
Protein (Log10 ug/mL) 2.12 (1.84–2.45) 1.99 (1.65–2.38) 2.13 (1.60–2.43) 2.13 (1.80–2.45) 0.85
% HIV inhibition
(BaL)
33.54 (25.52–43.12) 38.97 (30.74–52.20) 48.86 (45.93–
61.20)
59.30 (44.76–62.42) 0.26
% HIV inhibition
(RHPAc)
28.30 (17.08–48.74) 38.40 (20.41–43.91) 39.25 (34.72–
49.39)
34.17 (31.73–37.29) 0.53
2B. HIV Infected
Variable (Log10 pg/
mL)
Control Median
(IQR)
Depression Median
(IQR)
Abuse Median
(IQR)
Abuse+Depression Median
(IQR)
p
value
p value After Protein
Adjustment
n 10 10 8 10
TNF-α 1.12 (-1.3–1.40) 1.47 (1.18–1.52) 0.43 (-1.6–1.00) -1.6 (-1.6–0.06) <0.01 <0.01
IL-6 0.58 (0.27–1.00) 0.97 (0.86–1.16) 1.08 (1.01–1.24) 1.10 (0.88–1.14) 0.05 0.33
IL-1α 2.73 (2.46–2.83) 2.15 (1.69–2.81) 0.88 (0.58–1.71) 1.94 (0.42–2.23) 0.06 0.01
IL-1β 0.92 (0.31–1.89) 0.86 (0.31–1.06) 1.15 (0.31–1.63) 1.31 (0.31–1.88) 0.82 0.19
TGF-β 0.26 (0.26–0.26) 0.66 (0.26–1.71) 0.26 (0.26–1.73) 0.41 (0.26–1.57) 0.12 0.27
MIP-3α 1.36 (1.14–1.66) 1.05 (-0.67–1.27) -0.67 (-0.67–1.76) -0.67 (-0.67–0.67) <0.01 <0.01
IL-8 2.36 (2.15–2.93) 2.33 (1.95–2.93) 2.49 (2.27–3.26) 2.39 (1.67–2.87) 0.79 0.32
MCP-1 0.02 (0.02–1.94) 2.36 (1.68–2.58) 2.58 (2.28–2.75) 2.21 (1.78–2.54) 0.01 0.15
IP-10 2.90 (2.41–3.19) 2.72 (2.56–3.06) 2.36 (2.12–2.72) 2.20 (2.04–2.92) 0.51 0.27
(Continued)
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followed by the Control (1.12 log pg/mL) and Abuse (0.43 log pg/mL) groups with mostly
undetectable values for the Abuse+Depression group (p<0.01) (Fig 2D, Table 2B).
Differences observed for MIP-3α and TNF-α remained significant following protein adjust-
ment (Table 2B). However, IL-6 and MCP-1 were no longer significant (Table 2B). On the
other hand, Cathepsin B, IL-1α, and Gro-α were not significantly different before protein
adjustment, but did show significant differences after adjustment (Table 2B). Cathepsin B and
IL-1α concentrations were the lowest in the Abuse group (p<0.01, and p = 0.01, respectively),
whereas Gro-α concentrations were highest in the Abuse group (p = 0.03) (Table 2B).
Using linear regression analysis, following adjustment for CD4 and viral load, depressive
symptoms (after controlling for chronic sexual abuse) were associated with 1.00 pg/mL log
decrease of MIP-3α (p<0.01). Chronic sexual abuse (after controlling for depressive symp-
toms), was associated with a 0.79 pg/mL log increase of MCP-1 (p = 0.03), and a 0.75 pg/mL
log increase in Gro-α (p = 0.01). Chronic sexual abuse was also associated with a 1.16 pg/mL
log decrease of MIP-3α (p<0.01), 1.27 pg/mL log decrease of TNF-α (p<0.01), 0.71 pg/mL log
decrease of IL-1α (p = 0.02) and 0.30 pg/mL log decrease in Cathepsin B (p = 0.03) (Table 3B).
Adjustment to total protein did not change these results except increased IL-6 (p = 0.03) and
Serpin B1 (p = 0.04) were now significantly associated with chronic sexual abuse. Interaction
between chronic sexual abuse and depressive symptoms was significant for MCP-1 and FGF
before, but not after protein adjustment (Table 3B). Following protein adjustment, significant
interactions were noted for Cathepsin B (p<0.01), IL-1α (p = 0.02) and Cystatin A (p = 0.01)
(Table 3B).
Table 2. (Continued)
SLPI 4.72 (4.33–5.14) 4.96 (4.54–5.38) 5.17 (4.66–5.54) 4.44 (4.08–4.83) 0.28 0.56
Elafin 5.46 (5.10–5.57) 5.47 (5.08–5.72) 5.28 (5.04–5.66) 5.28 (5.06–5.40) 0.56 0.64
HBD-2 3.48 (3.04–4.43) 3.62 (3.17–4.15) 3.63 (2.96–4.21) 3.03 (2.69–4.34) 0.45 0.58
HNP1-3 4.10 (3.70–5.11) 3.70 (3.70–4.00) 3.90 (3.70–4.70) 3.70 (3.70–4.49) 0.64 0.25
TSP-1 3.06 (2.93–3.41) 3.03 (2.98–3.36) 3.01 (2.94–3.52) 3.02 (2.89–3.11) 0.72 0.55
Serpin A1 5.05 (4.89–5.53) 5.54 (5.19–5.80) 5.53 (5.20–5.67) 4.99 (4.43–5.97) 0.27 0.19
Serpin A5 1.47 (1.47–2.71) 1.47 (1.47–3.05) 2.70 (1.78–3.48) 2.89 (1.77–3.10) 0.15 0.29
Serpin B1 2.87 (2.87–4.19) 3.02 (2.87–3.63) 3.59 (2.87–4.42) 4.07 (3.31–4.26) 0.20 0.23
Cystatin A 4.54 (3.23–5.55) 3.23 (3.23–4.15) 3.23 (3.23–4.73) 3.23 (3.23–4.62) 0.36 0.1
Cystatin B 4.37 (3.58–4.53) 3.27 (2.86–4.17) 4.52 (3.64–4.92) 4.24 (3.51–4.78) 0.24 0.15
GRO-α 2.39 (0.89–2.82) 2.47 (0.89–2.55) 2.86 (2.61–3.31) 2.79 (2.62–3.07) 0.06 0.03
VEGF 0.79 (0.48–2.13) 1.76 (0.48–2.35) 2.06 (1.65–2.34) 1.94 (1.62–2.28) 0.61 0.35
PDGF 0.96 (0.63–1.75) 1.57 (0.63–2.78) 2.13 (1.79–2.22) 1.55 (0.63–2.41) 0.42 0.76
EGF -.24 (-.24–1.73) 0.87 (-.24–1.00) 0.42 (-.24–1.20) 0.56 (-.24–1.21) 0.97 0.75
FGF 1.73 (1.28–1.95) 2.39 (1.28–2.70) 2.20 (1.28–2.61) 1.28 (1.28–1.58) 0.19 0.78
IGF 1.65 (1.29–2.63) 1.29 (1.29–1.29) 1.29 (1.29–2.32) 1.29 (1.29–1.29) 0.32 0.54
Cathepsin B 4.13 (3.78–4.32) 4.06 (3.77–4.20) 3.56 (3.10–4.10) 4.07 (3.51–4.19) 0.37 <0.01
Protein (Log10 ug/mL) 2.13 (1.75–2.34) 2.25 (2.09–2.34) 2.41 (2.16–2.65) 2.05 (1.66–2.39) 0.24
% HIV inhibition
(BaL)
59.92 (46.58–75.28) 74.05 (68.12–94.12) 46.33 (39.70–
78.35)
63.92 (46.12–80.20) 0.24
% HIV inhibition
(RHPAc)
44.53 (31.67–67.46) 67.06 (51.75–95.42) 49.14 (29.21–
66.02)
67.31 (61.80–81.73) 0.15
CD4 Count 475 (395–660) 739 (523–1086) 693 (557–782) 539 (445–702) 0.06
Log Viral Load 1.46 (1.30–2.57) 1.69 (1.67–1.75) 1.30 (1.30–2.62) 2.42 (1.30–4.00) 0.58
https://doi.org/10.1371/journal.pone.0198412.t002
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Table 3. Main effects and Interaction models for the effects of depression and abuse on FRT biomarkers in HIV-uninfected (A) and HIV-infected (B) women. Lin-
ear regression models were used. Abuse defined as childhood sexual abuse and adult sexual abuse reported at baseline.
3A. HIV Uninfected
Model without Interaction Model with Interaction
Outcome
(Log10 pg/
mL)
Depressive
Symptoms vs
None
p
value
p value after
Protein
Adjustment
Abuse
vs None
p
value
p value after
Protein
Adjustment
Depressive
Symptoms vs
None
Abuse
vs None
Depression-
Abuse
Interaction
p
value
p value after
Protein
Adjustment
TNF-α 0.74 0.15 0.14 0.94 0.07 0.10 0.89 1.09 -0.32 0.75 0.67
IL-6 -0.40 0.13 0.19 0.54 0.05 0.09 -0.86 0.06 1.00 0.06 0.11
IL-1α 0.07 0.82 0.67 0.95 <0.01 <0.01 -0.69 0.15 1.67 0.01 <0.01
IL-1β -0.25 0.37 0.44 0.12 0.66 0.84 -0.71 -0.36 1.01 0.06 0.10
TGF-β 0.18 0.46 0.42 -0.71 <0.01 0.01 0.55 -0.33 -0.80 0.09 0.08
MIP-3α -0.02 0.96 0.94 0.68 0.04 0.05 -0.22 0.47 0.44 0.50 0.61
IL-8 -0.24 0.41 0.47 -0.12 0.69 0.51 -0.44 -0.32 0.42 0.47 0.59
MCP-1 0.02 0.94 0.84 -0.76 0.02 0.01 0.32 -0.45 -0.64 0.33 0.23
IP-10 0.37 0.08 0.08 0.67 <0.01 0.01 -0.11 0.16 1.06 0.01 0.04
SLPI -0.15 0.54 0.63 0.27 0.25 0.35 -0.33 0.08 0.40 0.41 0.55
Elafin 0.02 0.84 0.66 -0.02 0.84 0.54 -0.14 -0.19 0.35 0.13 0.45
HBD-2 0.04 0.88 0.70 -0.04 0.86 0.60 -0.20 -0.29 0.51 0.27 0.35
HNP1-3 -0.20 0.40 0.45 0.23 0.35 0.45 -0.28 0.15 0.17 0.73 0.92
TSP-1 0.06 0.69 0.52 0.25 0.09 0.24 -0.08 0.10 0.30 0.30 0.57
Serpin A1 -0.12 0.61 0.62 -0.01 0.97 0.64 -0.54 -0.45 0.91 0.05 0.01
Serpin A5 0.13 0.54 0.53 0.04 0.84 0.94 0.23 0.14 -0.21 0.64 0.55
Serpin B1 0.14 0.46 0.34 0.53 0.01 0.02 0.08 0.46 0.13 0.73 0.99
Cystatin A -0.04 0.89 0.99 -0.10 0.76 0.65 -0.08 -0.14 0.08 0.90 0.95
Cystatin B -0.09 0.80 0.88 -0.29 0.39 0.26 -0.87 -1.12 1.71 0.01 0.01
GRO-α 0.17 0.61 0.49 0.54 0.11 0.13 -0.16 0.20 0.72 0.29 0.34
VEGF -0.08 0.76 0.84 0.37 0.16 0.14 -0.24 0.21 0.34 0.53 0.62
PDGF -0.28 0.18 0.25 -1.49 <0.01 <0.01 -0.16 -1.36 -0.26 0.53 0.35
EGF -0.47 0.07 0.14 -0.39 0.14 0.13 -0.53 -0.44 0.12 0.82 0.99
FGF 0.13 0.05 0.26 0.14 0.04 0.64 0.00 0.00 0.28 0.03 0.61
IGF 0.14 0.55 0.49 0.23 0.33 0.54 -0.09 -0.01 0.49 0.30 0.49
Cathepsin B -0.10 0.51 0.66 -0.15 0.34 0.11 -0.16 -0.21 0.12 0.69 0.98
3B. HIV Infected
Model without Interaction Model with Interaction
Outcome
(Log10 pg/
mL)
Depressive
Symptoms vs
None
p
value
p value after
Protein
Adjustment
Abuse
vs None
P
value
p value after
Protein
Adjustment
Depressive
Symptoms vs
None
Abuse
vs None
Depression-
Abuse
Interaction
p
value
p value after
Protein
Adjustment
TNF-α -0.06 0.89 0.96 -1.27 <0.01 <0.01 0.57 -0.56 -1.33 0.11 0.36
IL-6 0.04 0.79 0.49 0.36 0.08 0.03 0.26 0.61 -0.47 0.16 0.69
IL-1α 0.09 0.77 0.58 -0.71 0.02 0.02 -0.26 -1.11 0.74 0.22 0.02
IL-1β -0.10 0.69 0.92 0.25 0.41 0.31 -0.21 0.12 0.24 0.63 0.07
TGF-β 0.32 0.19 0.11 0.16 0.64 0.50 0.72 0.62 -0.86 0.07 0.59
MIP-3α -1.00 <0.01 <0.01 -1.16 <0.01 <0.01 -1.00 -1.15 0.00 0.99 0.31
IL-8 -0.38 0.17 0.18 0.08 0.91 0.78 -0.33 0.13 -0.11 0.85 0.28
MCP-1 0.34 0.29 0.21 0.79 0.03 0.02 1.01 1.54 -1.42 0.02 0.21
IP-10 -0.04 0.86 0.88 -0.21 0.32 0.30 0.00 -0.17 -0.08 0.85 0.33
SLPI -0.05 0.83 0.89 -0.05 0.64 0.84 0.26 0.30 -0.65 0.16 0.92
Elafin -0.06 0.75 0.91 -0.13 0.31 0.47 0.10 0.05 -0.33 0.35 0.43
HBD-2 -0.05 0.84 0.92 -0.30 0.13 0.25 0.16 -0.06 -0.44 0.40 0.72
(Continued)
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Effect modifications by HIV status
In analyzing the differences between HIV uninfected and HIV infected women by depression
or abuse status (Table 4), we observed the association between MIP-3α and depression was sig-
nificantly lower (p = 0.03) in HIV infected women compared to HIV uninfected women. The
association between MIP-3α and abuse was also significantly lower (p<0.01) in HIV infected
compared to HIV uninfected women. Whereas none of the other mediators showed a differen-
tial association with depression by HIV status, the association between abuse and TNF-α
(p<0.01), IL-1α (p<0.01) and IP-10 (p<0.01) was significantly lower in HIV infected com-
pared to uninfected women. Conversely, the association between abuse and MCP-1 (p<0.01)
and PDGF (p<0.01) was significantly higher in HIV infected compared to uninfected women.
Anti-HIV activity
Previously, we have demonstrated intrinsic HIV inhibitory activity in CVL and its association
with immune mediators as well as clinical parameters such as CD4 counts [45,46]. Using the
TZM-bl assay for HIV infection, we investigated whether abuse or depression status impacts
functional anti-HIV activity in CVL. Although we observed a wide range of inhibition in all
eight groups, we did not find significant differences in anti-HIV activity based on abuse or
depression status in either HIV-infected or HIV-uninfected women (Table 1A and 1B). This
observation held true for both inhibitory activity against the laboratory-adapted strain BaL, as
well as the heterosexually transmitted T/F strain RHPA.c (Table 1A and 1B). As expected,
CVL from the HIV-infected individuals in our cohort showed better inhibitory activity com-
pared to the HIV-uninfected individuals, as they were all on HAART. Interestingly, however,
several HIV-infected individuals did not inhibit the virus at all in spite of being on HAART.
This could point toward lack of adherence or general dysregulation of FRT immunity.
Changes in immune mediator (cytokine/chemokine/antimicrobial)
network
Distinct immune clusters have been described previously in the context of HIV infection and
susceptibility [47]; associations between immune mediators are important to consider as they
can interact synergistically or antagonistically and be clinically predictive [48–51]. For soluble
immune mediators tested, we saw significantly altered clustering patterns in Abuse groups
Table 3. (Continued)
HNP1-3 -0.30 0.22 0.32 0.01 0.87 0.96 -0.37 -0.07 0.16 0.75 0.09
TSP-1 -0.07 0.55 0.96 -0.06 0.49 0.62 0.04 0.06 -0.22 0.33 0.21
Serpin A1 0.04 0.84 0.48 -0.19 0.16 0.38 0.40 0.22 -0.76 0.07 0.64
Serpin A5 0.06 0.81 0.64 0.53 0.11 0.05 0.16 0.64 -0.20 0.71 0.50
Serpin B1 0.04 0.85 0.64 0.44 0.11 0.04 -0.04 0.36 0.16 0.70 0.11
Cystatin A -0.43 0.19 0.23 -0.26 0.29 0.43 -0.79 -0.67 0.77 0.23 0.01
Cystatin B -0.37 0.14 0.30 0.39 0.25 0.13 -0.54 0.20 0.36 0.49 0.09
GRO-α -0.06 0.81 0.96 0.75 0.01 0.01 0.00 0.82 -0.13 0.81 0.33
VEGF 0.07 0.80 0.57 0.41 0.17 0.17 0.29 0.66 -0.46 0.44 0.78
PDGF -0.09 0.76 0.95 0.32 0.40 0.30 0.28 0.74 -0.79 0.21 0.78
EGF 0.09 0.74 0.53 -0.05 0.71 0.86 0.15 0.02 -0.13 0.81 0.38
FGF 0.07 0.76 0.54 -0.07 0.60 0.75 0.48 0.40 -0.88 0.04 0.56
IGF -0.37 0.07 0.28 -0.08 0.64 0.70 -0.50 -0.22 0.26 0.51 0.11
Cathepsin B 0.14 0.40 0.16 -0.30 0.03 0.08 -0.01 -0.47 0.33 0.33 <0.01
https://doi.org/10.1371/journal.pone.0198412.t003
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compared to Control in both HIV-uninfected (Fig 3A i-iv) and HIV-infected populations (Fig
3B i-iv).
In HIV-uninfected Abuse (Fig 3A, iii), strong positive interactions were observed between
chemokines (MIP-3α, IL-8, MCP-1) and cytokines (IL-6, IL-1α, IL-1β). A strong grouping of
positive interactions was also observed between these cytokines and chemokines with anti-
HIV factors HNP 1–3, TSP-1 and Serpin A1. Finally, Gro-α and Cathepsin B associated signifi-
cantly with multiple immune biomarkers. None of these patterns (shown as boxes on the heat-
maps) were present in Control, Depression and Abuse+Depression groups (Fig 3A i, ii, iv).
Overall, the Abuse group showed the maximum number of significant associations (47 positive
and 4 negative).
Associations among biomarkers were distinct in the HIV-infected population (Fig 3B i-iv).
In the Abuse group, strong positive interactions were observed between the pro-inflammatory
cytokine TNF-α and chemokines (MCP-1, IP-10), anti-HIV mediators (Cystatin A), growth
Fig 2. Differences in cervico-vaginal immune mediators by abuse status in HIV-infected women. CVL from Control women with no history of sexual abuse and
depression (n = 10), women with current depression (n = 10), women with history of chronic sexual abuse (n = 8), and women with history of chronic sexual abuse and
current depression (n = 10), were tested for levels of (A) MIP-3α, (B) MCP-1, (C) IL-6, (D) TNF-α, by standard ELISA assays. Data is presented as log pg/mL of protein.
Bars depict median. P value is indicated as follows: , p<0.0001, , P<0.001, , P<0.05.
https://doi.org/10.1371/journal.pone.0198412.g002
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factors (PDGF, EGF), protease (Cathepsin B) and HIV BaL inhibition. There was also a strong
cluster between growth factors (PDGF, EGF, FGF, IGF) with chemokines (MCP-1, IP-10),
anti-HIV factors (SLPI, Elafin) and protease (Cathepsin B). PDGF and EGF also associated sig-
nificantly with inhibition of HIB BaL and RHPA. As with the HIV uninfected, none of the
associations in Abuse (shown as boxes on the heat-maps) were present in Control, Depression,
and Abuse+Depression (Fig 3B, i, ii, iv). Interestingly, in both HIV-uninfected and infected
categories, immune associations in Abuse+Depression did not resemble the patterns in either
Abuse or Depression.
Discussion
Our data indicate that exposure to chronic sexual abuse and current depressive symptoms can
be associated with immune alterations which can include a state of inflammation, immune
activation, and modified wound healing pathways within the FRT, thereby increasing risk of
HIV acquisition/transmission. These findings have clinical implications in HIV prevention
efforts, as therapies that abate inflammation and immune activation (such as using anti-
inflammatory drugs, [52]) and modulate wound healing [53], could be applied to reduce risks
of HIV infection in women who have histories of abuse and depression. Fig 4 shows a sche-
matic of our hypothesis and major findings.
Table 4. Main effects and interaction models for the effects of depression and abuse on systemic biomarkers, by HIV status. Linear regression models were used.
Abuse defined as childhood sexual abuse and adult sexual abuse reported at baseline.
Outcome (Log10
pg/mL)
Change in Outcome,
Depression vs None
Change in Outcome,
Abuse vs None
Change in Outcome,
HIV+ vs HIV
HIV Abuse
Interaction
p value HIV Depression
Interaction
p
value
TNF-α 0.74 0.94 1.26 -2.21 <0.01 -0.79 0.23
IL-6 -0.40 0.54 0.43 -0.18 0.57 0.45 0.15
IL-1α 0.07 0.95 0.82 -1.66 <0.01 0.02 0.97
IL-1β -0.25 0.12 -0.21 0.13 0.73 0.15 0.68
TGF-β 0.18 -0.71 -0.58 0.88 0.01 0.14 0.68
MIP-3α -0.02 0.68 0.73 -1.84 <0.01 -0.98 0.03
IL-8 -0.24 -0.12 0.03 0.19 0.63 -0.14 0.72
MCP-1 0.02 -0.76 -0.04 1.55 <0.01 0.31 0.49
IP-10 0.37 0.67 1.12 -0.88 <0.01 -0.41 0.16
SLPI -0.15 0.27 0.06 -0.32 0.33 0.10 0.76
Elafin 0.02 -0.02 0.10 -0.10 0.62 -0.08 0.70
HBD-2 0.04 -0.04 0.11 -0.26 0.46 -0.09 0.80
HNP1-3 -0.20 0.23 -0.18 -0.21 0.53 -0.10 0.77
TSP-1 0.06 0.25 0.30 -0.30 0.10 -0.13 0.49
Serpin A1 -0.12 -0.01 0.16 -0.18 0.57 0.16 0.61
Serpin A5 0.13 0.04 0.27 0.49 0.15 -0.07 0.84
Serpin B1 0.14 0.53 0.02 -0.09 0.76 -0.10 0.72
Cystatin A -0.04 -0.10 -0.35 -0.16 0.72 -0.38 0.40
Cystatin B -0.09 -0.29 0.08 0.68 0.11 -0.29 0.49
GRO-α 0.17 0.54 0.36 0.21 0.62 -0.23 0.59
VEGF -0.08 0.37 0.53 0.04 0.92 0.16 0.69
PDGF -0.28 -1.49 -1.46 1.81 <0.01 0.18 0.62
EGF -0.47 -0.39 -0.41 0.34 0.36 0.57 0.13
FGF 0.13 0.14 0.65 -0.21 0.37 -0.06 0.78
IGF 0.14 0.23 0.31 -0.31 0.32 -0.51 0.10
Cathepsin B -0.10 -0.15 -0.22 -0.15 0.51 0.24 0.29
https://doi.org/10.1371/journal.pone.0198412.t004
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Fig 3. Heat map of Spearman’s coefficients for HIV-uninfected (A) and HIV-infected (B) samples stratified by
abuse and depression status. Distinct associative patterns were observed among (A i-iv) HIV negative Control,
Depression, Abuse, Abuse+Depression as well as (B i-iv) HIV-infected Controls, Depression, Abuse and Abuse
+Depression. Each cell of the heat map denotes the Spearman correlation coefficients. Cells highlighted in shades of
RED indicates a positive association with darker shades representing stronger associations. Similarly, cells highlighted
in shades of BLUE indicates a negative association with darker shades representing stronger associations. Statistically
significant (p<0.05) associations are denoted in BOLD. Missing numbers (white) indicate there was no variation
within that subgroup usually due to undetectable values, therefore the correlation coefficient could not be calculated.
Boxed-in sections highlight clustering patterns.
https://doi.org/10.1371/journal.pone.0198412.g003
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In HIV-uninfected women, we found significantly higher levels of pro-inflammatory cyto-
kine IL-1α and chemokine IP-10 in Abuse+Depression group compared to Controls, indicat-
ing inflammation/immune activation. This was coupled with significantly lower levels of
PDGF in both Abuse and Abuse+Depression groups compared to Controls. Growth factors,
such as PDGF, play a critical role in early stages of wound healing by initiating the process of
formation of blood clots [14], [12]. Genital wound healing has been associated with hormonal
contraceptive usage, as well as menopause [8]. Impaired wound healing in the HIV-infected
population has been described in cases of adult male circumcision [54] but little is known
regarding biomarkers of wound healing in women experiencing chronic sexual abuse. Our
finding of decreased PDGF in women experiencing chronic sexual abuse suggests wound heal-
ing mechanisms might not be optimally functional in this population. Our linear regression
models also confirmed associations between chronic sexual abuse and increases in inflamma-
tion/immune activation biomarkers (MIP-3α, IP-10, and IL-1α) along with decreases in fac-
tors associated with wound-healing (PDGF and TGF-β). TGF-β is a pleiotropic cytokine that
is involved in all stages of wound repair [55]. As HIV is known to show enhanced infection in
presence of genital inflammation and epithelial breach [13], [56] increased inflammation
(higher IL-1α and IP-10), coupled with impaired wound healing could be detrimental for
these women in terms of HIV acquisition.
In HIV-infected women, we found significantly increased levels of IL-6 and MCP-1 in
Abuse groups compared to Controls, which can be indicative of inflammation and immune
activation. Increased levels of IL-6 in HIV-infected women has been shown to be associated
with inflammation and HIV genital tract shedding, resulting in increased risk for HIV
Fig 4. Hypothetical model of interaction between exposure to chronic sexual abuse, depression, immune dysregulation and HIV susceptibility. Our model
hypothesizes that exposure to sexual abuse can directly result in immune dysregulation leading to increased HIV susceptibility. Depression resulting from exposure to
sexual abuse can also lead to immune dysregulation and increased HIV susceptibility. Our major findings are also summarized schematically. Immune mediators are
shown as gradients with the wider end of the arrows denoting groups where the concentrations were higher.
https://doi.org/10.1371/journal.pone.0198412.g004
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transmission [57], [58]. MCP-1 has been associated with chronic mucosal inflammation and
increased levels have been reported in HIV infected individuals [59], [60], [61], [62]. In con-
trast, we observed significantly decreased levels of pro-inflammatory cytokines IL-1α, TNF-α
and chemokine MIP-3α in Abuse+Depression groups compared to Controls. It is possible that
since all the HIV-infected women were on HAART, certain inflammatory pathways were sup-
pressed. However, it has also been shown that HAART does not completely suppress systemic
chronic inflammation [21]. Our data confirms and extends these findings in the FRT showing
suppression of certain inflammatory pathways, but not others in HIV-infected women
experiencing chronic sexual abuse. Further, MIP-3α also functions as an anti-HIV antimicro-
bial [63] and therefore its significant downregulation in Abuse+Depression groups can imply
lack of protection against HIV.
While most studies quantify levels of individual immune mediators, changes observed at
the individual level do not reflect how these mediators interact with each other in vivo where
they are present concurrently, in a given tissue or biological fluid. Previous reports have shown
that immune mediators can interact synergistically or antagonistically and be clinically predic-
tive [48–51]. A heat-map analysis is designed to show correlations or associations between
immune mediators which implies cross-talk among the mediators independent of their abso-
lute levels. In a study by Lisco et. al., the authors reported distinct clustering of cytokines in
semen and blood of HIV infected versus HIV uninfected men, with significantly more associa-
tions observed in the infected population. The authors speculated that the multiple associa-
tions result in a rigidity in cytokine network and may result in the loss of immune flexibility
that is required for efficient functioning of the immune system [47]. In our cohort, Abuse
groups showed the most associations and therefore most rigidity, particularly in mediators
associated with inflammation. Therefore, it is possible that this level of interdependent engage-
ment can be detrimental in terms of the immune system to respond to pathogens. This concept
is speculative at this stage and must be verified by experimental data.
One interesting observation in the heat-maps was the distinct patterns of strong positive
associations among growth factors in Depression and Abuse groups compared to Controls.
Recent studies indicate potential involvement of growth factors, along with inflammatory cyto-
kines with major depressive symptoms [26,64]. Further, our Abuse+Depression groups also
reported increased substance abuse, alcohol consumption and smoking compared to Controls
(Table 1), which has been reported by multiple studies to cause general immune dysfunction
and impair wound healing pathways (reviewed [14]). Mechanisms involving growth factors in
Abuse and Depression in the FRT has not been previously shown and needs to be further
elucidated.
Another finding in the present study was that the extent of significance in changes in some
of the immune mediators varied depending on whether we adjusted for total protein content.
However, CVL total protein content was not significantly different among our groups
(Table 2A and 2B). In previous studies, we have reported significantly higher CVL protein
content in pregnant women compared to non-pregnant women [44], but not in premeno-
pausal compared to postmenopausal women [39]. Whether the changes in significance that we
observe in the present study are biologically relevant is not clear at this point. Further studies
are needed to understand whether immune protection in the FRT is altered as a result of these
changes.
To our knowledge, this is the first study to characterize a large panel of genital biomarkers
in the context of sexual abuse and HIV. Other than the frequently analyzed cytokines/chemo-
kines, we also extended our panel to include anti-HIV/anti-proteases and mediators associated
with wound healing. There were several limitations to this study design including small sample
sizes, use of extreme phenotypes, and the use of a samples from a pre-existing cohort. Small
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sample sizes limit the statistical power of the observations, which limits the ability to see small
but statistical differences that might exist between groups. Extreme phenotypes were selected
in order to maximize potential differences between groups, but these selection criteria also lim-
ited the pool of potential samples. Although we selected our Control groups to have no recent
abuse of any type, we were not able to control for any non-sexual abuse in their past. Finally,
use of samples from an existing cohort means that we could not control for a number of
parameters or have control over recorded demographic data. In spite of these limitations and
strict criteria of selection of extreme phenotypes, our data does point to immune alterations in
FRT of women exposed to chronic sexual abuse. Additional studies with larger sample sizes
are warranted to understand the underlying mechanisms further.
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